patient
undergo
thorac
organ
transplant
procedur
involv
heart
lung
increas
risk
develop
wide
varieti
infect
due
underli
immunosuppress
andor
factor
lung
transplant
recipi
high
risk
develop
infect
caus
bacteria
virus
opportunist
fungi
wherea
heart
transplant
recipi
risk
develop
infect
caus
microorgan
well
parasit
infect
includ
toxoplasmosi
new
world
trypanosomiasi
review
highlight
variou
infect
thorac
organ
transplant
recipi
may
develop
follow
procedur
lung
transplant
viabl
treatment
option
patient
endstag
emphysema
poorli
treat
lung
diseas
lung
heartlung
transplant
perform
unit
state
compar
solidorgan
transplant
sot
recipi
lung
transplant
lt
recipi
shorter
surviv
time
lt
patient
typic
surviv
respect
infect
major
caus
death
often
link
reject
commonli
manifest
bronchiol
obliteran
bo
certain
infect
may
trigger
bo
bo
increas
risk
opportunist
infect
pneumonia
perhap
common
infect
lung
recipi
lead
caus
death
first
year
infect
risk
lt
recipi
similar
risk
sot
recipi
relat
immunosuppress
reject
infect
statu
donor
recipi
prophylaxi
time
interv
sinc
transplant
lung
howev
sever
uniqu
infect
risk
constant
exposur
environ
limit
vascular
bronchial
anastomot
site
disrupt
lymphat
compromis
cough
reflex
impair
mucociliari
function
exposur
colon
pathogen
nativ
lung
four
five
infect
lt
recipi
occur
mediastinum
pleural
space
lung
pneumonia
account
oneto
twothird
bloodstream
infect
occur
approxim
lt
recipi
aris
lung
perhap
heavi
bacteri
colon
nativ
lung
cystic
fibrosi
patient
appear
higher
rate
bacteremia
bronchial
anastomot
site
infect
infrequ
seriou
one
chart
review
heartlung
lt
recipi
show
anastomot
site
infect
aspergillu
candida
staphylococcu
aureu
seri
patient
dehisc
other
anastomot
ruptur
infect
brain
central
nervou
system
cn
occur
lt
recipi
mostli
due
aspergillu
nocardia
due
arteri
invas
aspergillu
hemorrhag
infarct
occur
mortal
high
cn
aspergillu
infect
bacteria
account
major
infect
lt
recipi
bacteri
bronchiti
pneumonia
occur
patient
mani
patient
case
pneumonia
occur
within
first
month
posttransplant
bacteri
infect
may
also
complic
bo
mani
transplant
center
cultur
tracheal
aspir
recipi
donor
provid
specif
antibiot
prophylaxi
bacteria
grow
burkholderia
cepacia
pseudomona
aeruginosa
particular
concern
sinc
often
colon
nativ
lung
resist
multipl
antibiot
transplant
program
perform
transplant
patient
colon
resist
burkholderia
pseudomona
instanc
shown
patient
colon
burkholderia
cenocepacia
genovar
iii
much
lower
surviv
rate
patient
colon
speci
b
cepacia
complex
reason
mani
transplant
program
may
refus
perform
transplant
patient
colon
b
cenocepacia
surgeon
perform
transplant
patient
colon
bacteria
often
use
broadspectrum
antibiot
prophylaxi
periand
postop
period
cystic
fibrosi
patient
singl
lt
may
greater
risk
pneumonia
nativ
lung
function
reservoir
resist
pathogen
laboratori
diagnosi
commonli
encount
bacteri
infect
requir
use
routin
cultur
media
along
manual
autom
identif
antimicrobi
suscept
method
organ
fulli
identifi
antibiot
suscept
result
avail
within
h
howev
fastidi
andor
uncommon
organ
may
need
use
special
media
incub
condit
requir
addit
time
isol
complet
identif
although
legionella
caus
agent
legionnair
diseas
commonli
afflict
immunocompromis
patient
rare
report
pathogen
lt
patient
diagnosi
usual
made
cultur
urinari
antigen
test
occasion
pcr
legionella
antibodi
test
singl
acutephas
serum
pair
sera
may
use
nocardia
spp
caus
soft
tissu
infect
lung
infect
brain
abscess
lung
heartlung
transplant
commonli
year
transplant
incid
cn
infect
may
requir
surgeri
diagnosi
manag
see
heart
transplant
laboratori
diagnosi
nocardia
spp
mycobacterium
tuberculosi
report
lt
recipi
one
spanish
studi
lt
patient
found
case
activ
tuberculosi
six
diagnos
via
histolog
examin
explant
lung
underw
therapi
five
remain
patient
develop
evid
subclin
diseas
month
eventu
develop
symptom
patient
without
symptom
posit
tuberculosi
cultur
bronchoalveolar
lavag
see
heart
transplant
laboratori
diagnosi
tuberculosi
half
patient
die
end
studi
case
attribut
bo
interestingli
patient
ppd
posit
time
transplant
receiv
prophylaxi
develop
activ
tuberculosi
tuberculosi
therapi
transplant
patient
complic
sever
drug
interact
rifampin
calcineurin
inhibitor
approxim
two
dozen
case
nontubercul
mycobacteri
ntm
infect
report
lt
recipi
includ
mycobacterium
avium
complex
mycobacterium
haemophilum
mycobacterium
kansasii
mycobacterium
marinum
mycobacterium
asiaticum
mycobacterium
fortuitum
mycobacterium
abscessu
mycobacterium
chelona
incid
rate
ntm
infect
lt
recipi
lt
recipi
chronic
reject
increas
risk
ntm
infect
infect
occur
lung
pleura
organ
present
environ
innocu
colon
bronchial
tree
make
diagnosi
difficult
therapi
often
last
month
guid
cultur
suscept
test
result
betaherp
viru
cytomegaloviru
cmv
common
opportunist
pathogen
lt
patient
bacteria
compar
sot
lung
heartlung
transplant
patient
cmv
diseas
incid
individu
receiv
prophylaxi
may
due
higher
degre
immunosuppress
therapi
use
patient
compar
transplant
recipi
besid
lifethreaten
pneumon
cmv
caus
hepat
enter
coliti
transplant
cmv
may
also
predispos
individu
bacteremia
aspergillu
infect
epsteinbarr
viru
ebv
relat
posttranspl
lymphoprolif
diseas
ptld
worrisom
cmv
diseas
associ
bo
differ
strategi
employ
prevent
cmv
diseas
lt
see
heart
transplant
laboratori
diagnosi
cmv
commonli
prophylaxi
valganciclovir
use
due
eas
administr
lung
transplant
longer
cours
month
greater
antivir
therapi
may
use
ganciclovir
resist
may
occur
requir
treatment
higher
dose
ganciclovir
foscarnet
high
dose
increas
side
effect
bone
marrow
suppress
specif
leukopenia
alphaherpesvirus
herp
simplex
hsv
varicella
zoster
viru
vzv
often
complic
posttranspl
period
one
studi
show
heartlung
transplant
patient
develop
mucocutan
herp
infect
hsv
pneumon
occur
heartlung
recipi
zoster
afflict
lt
recipi
initi
vzv
infect
may
caus
viscer
diseas
case
rare
caus
meningoenceph
contrast
ebv
gammaherpesviru
infect
peopl
age
one
heartlung
transplant
patient
form
ebv
reactiv
half
experienc
sore
throat
fever
malais
ebv
also
associ
ptld
although
estim
vari
incid
ptld
lt
recipi
may
exceed
rate
solid
organ
transplant
mortal
ptld
reactiv
betaherpesviru
human
herp
viru
infect
caus
distinct
clinic
syndrom
lt
recipi
meningoenceph
case
may
trigger
bo
one
studi
show
lung
heartlung
transplant
recipi
evid
reactiv
approxim
day
posttranspl
seven
patient
die
within
month
communityacquir
respiratori
virus
respiratori
syncyti
viru
rsv
parainfluenza
viru
influenza
viru
adenoviru
rhinoviru
coronaviru
human
metapneumoviru
enteroviru
infect
immunocompromis
immunocompet
patient
lt
recipi
may
present
atyp
symptom
subtl
decreas
pulmonari
function
viral
shed
often
prolong
addit
respiratori
viral
infect
risk
factor
acut
chronic
reject
comparison
lt
recipi
respiratori
viral
infect
without
infect
infect
patient
develop
bo
month
postinfect
compar
none
uninfect
cohort
patient
popul
laboratori
diagnosi
viral
infect
may
requir
use
routin
cell
cultur
shell
vial
cell
cultur
immunofluoresc
techniqu
rapid
immunoblot
enzym
immunoassay
eia
test
molecular
analysi
due
rel
low
sensit
specif
mani
rapid
test
confirmatori
test
method
usual
requir
use
molecular
analysi
becom
commonplac
specif
multiplex
molecular
test
detect
increas
mix
viral
infect
previous
detect
use
tradit
viral
cultur
method
signific
mix
viral
infect
fulli
known
preliminari
find
show
increas
sever
diseas
case
may
impact
care
treatment
patient
fungal
infect
occur
lt
recipi
candida
spp
current
third
common
caus
bloodstream
infect
isol
candida
spp
respiratori
tract
typic
indic
colon
invas
candidiasi
usual
treat
howev
immunocompromis
transplant
patient
candidemia
may
lead
metastat
infect
half
time
compar
immunocompet
person
addit
candida
spp
may
caus
anastomot
infect
usual
diagnos
bronchoscopi
perhap
fear
pathogen
lt
recipi
aspergillu
spp
caus
asymptomat
colon
isol
tracheobronchi
infect
invas
pneumonia
system
infect
airway
colon
rate
report
estim
progress
diseas
aspergillu
tracheobronch
ulcer
pseudomembran
eschar
bronchial
sutur
line
dehisc
anastomot
infect
bronchial
stenosi
may
occur
within
month
lt
patient
less
patient
develop
invas
aspergillosi
usual
within
first
posttranspl
period
though
infect
occur
year
overal
incid
invas
aspergillosi
rang
lt
recipi
invas
aspergillosi
tracheobronch
carri
mortal
respect
besid
lung
aspergillu
may
invad
cn
one
retrospect
studi
lung
heartlung
heart
transplant
ht
recipi
found
aspergillu
brain
abscess
period
die
aspergillu
diseas
may
preced
follow
reject
detect
mold
prompt
search
reject
patient
bo
may
need
surveil
aspergillu
lipid
formul
amphotericin
b
caspofungin
voriconazol
use
success
treatment
third
common
invas
fungu
among
transplant
recipi
cryptococcu
neoforman
caus
pneumonia
dissemin
diseas
lt
patient
incid
mening
perhap
bit
less
sot
recipi
also
caus
primari
cellul
skin
nodul
pneumocysti
jirovecii
pneumonia
may
afflict
lt
recipi
receiv
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
repres
higher
incid
diseas
sot
recipi
prevent
therapi
incid
infect
low
fungal
infect
also
increas
lt
patient
diseas
fusarium
spp
may
rise
caus
lung
nodul
endocard
skin
lesion
heartlung
transplant
lt
patient
although
scedosporium
infect
may
rare
lt
recipi
may
becom
common
one
transplant
center
scedosporium
apiospermum
isol
respiratori
cultur
lung
transplant
recipi
three
recipi
cystic
fibrosi
posit
cultur
apiospermum
prior
transplant
see
heart
transplant
fungal
laboratori
diagnosi
posttranspl
infect
patient
appear
colon
patient
dissemin
diseas
develop
patient
develop
dissemin
diseas
die
median
time
transplant
onset
infect
month
rang
month
ht
perform
decad
complet
yearli
us
patient
surviv
first
year
transplant
even
though
reject
common
caus
death
first
year
transplant
infect
common
caus
death
later
posttranspl
period
infect
occur
transplant
commonli
organ
time
period
sinc
transplant
month
month
greater
month
base
risk
net
immunosuppress
epidemiolog
exposur
although
ht
recipi
suscept
infect
infect
uniqu
popul
includ
infect
relat
ventricular
assist
devic
vad
present
prior
transplant
toxoplasmosi
new
world
trypanosomiasi
review
organ
infect
may
present
ht
recipi
ht
recipi
particularli
earli
postop
period
risk
hospitalacquir
infect
includ
bacteri
pneumonia
patient
bacteremia
approxim
caus
pathogen
usual
bacteri
agent
caus
hospitalrel
infect
includ
aureu
coagulaseneg
staphylococci
p
aeruginosa
member
enterobacteriacea
multidrug
resist
gramneg
bacteria
increas
frequenc
worldwid
present
posttranspl
patient
well
patient
bacteremia
develop
complic
endocard
transplant
heart
ht
recipi
also
risk
develop
mediastin
higher
rate
undergo
thoracotomi
procedur
patient
requir
vad
prior
transplant
higher
risk
infect
patient
vad
individu
suscept
bacteremia
vad
endocard
pocket
infect
drive
line
infect
mediastin
clostridium
difficileassoci
diarrhea
occur
ht
recipi
present
similar
normal
host
diseas
may
often
sever
recent
studi
suggest
oral
vancomycin
prefer
therapi
sever
c
difficileassoci
diarrhea
diagnosi
made
use
latex
agglutin
assay
toxin
b
concurr
glutam
dehydrogenas
commonantigen
test
eia
cultur
cytox
assay
molecular
gene
amplic
assay
ht
recipi
also
risk
opportunist
bacteri
infect
listeriosi
nocardiosi
listeria
monocytogen
nocardia
sp
infect
usual
occur
within
first
month
transplant
patient
recent
undergon
treatment
reject
due
impair
cellmedi
immun
use
tmp
smx
prevent
p
jirovecii
infect
also
use
prevent
infect
caus
organ
listeriosi
quit
uncommon
sot
recipi
diseas
usual
begin
gastrointestin
symptom
progress
bacteremia
bacterium
predilect
cn
caus
mening
well
review
show
nocardia
infect
occur
ht
recipi
nocardiosi
usual
present
pulmonari
diseas
progress
cn
involv
diagnosi
made
biopsi
cultur
infect
site
laboratori
must
specif
notifi
look
nocardia
spp
organ
grow
slowli
may
overgrown
routin
bacteria
howev
fungal
cultur
typic
allow
extra
incub
time
requir
isol
organ
gram
stain
examin
clinic
materi
may
demonstr
gramposit
filament
branch
bead
rod
weakli
acidfast
appear
bead
morpholog
test
use
identif
nocardia
spp
includ
hydrolysi
gelatin
casein
xanthin
tyrosin
ii
growth
iii
acid
product
rhamnos
iv
antibiot
suscept
pattern
v
variou
molecular
technolog
nucleic
acid
sequenc
mass
spectrometri
mycobacteri
infect
also
concern
ht
recipi
reactiv
tuberculosi
occur
patient
usual
occur
first
month
transplant
like
develop
reject
present
treatment
similar
diseas
nontranspl
recipi
howev
onethird
onehalf
case
activ
tuberculosi
transplant
dissemin
occur
extrapulmonari
site
compar
case
healthi
host
caution
exercis
treat
either
latent
activ
tuberculosi
transplant
recipi
due
rifamycin
interact
immunosuppress
agent
cultur
laboratori
diagnosi
tuberculosi
infect
reli
use
broth
andor
solid
media
newer
autom
broth
method
detect
mycobacteri
speci
within
day
week
incub
solid
agar
method
may
take
week
posit
broth
agar
cultur
may
supplement
molecular
probe
identifi
specif
speci
recent
year
rapid
molecular
method
success
use
reli
earli
clinic
suspicion
dna
probe
assay
base
two
sequenc
databas
report
one
use
speci
identif
tuberculosi
rifampin
resist
special
media
condit
may
requir
cultur
nonm
tuberculosi
strain
haemophilum
mycobacterium
genavens
cmv
ebv
caus
signific
diseas
ht
recipi
either
donor
recipi
latent
cmv
infect
cmv
usual
reactiv
within
first
month
transplant
without
form
prevent
therapi
highest
risk
occur
donor
seroposit
cmv
recipi
seroneg
cmv
mismatch
risk
recipi
develop
primari
cmv
infect
situat
high
cmv
diseas
usual
present
fever
malais
myalgia
bone
marrow
suppress
endorgan
diseas
occur
may
involv
gastrointestin
tract
lung
heart
liver
brain
cmv
also
immunomodulatori
effect
activ
cmv
infect
found
independ
risk
factor
develop
infect
invas
fungal
diseas
ebvrel
ptld
cmv
also
implic
caus
acut
chronic
allograft
injuri
acceler
coronari
arteri
diseas
ht
recipi
two
strategi
commonli
use
prevent
direct
indirect
effect
cmv
infect
preemptiv
therapi
univers
prophylaxi
preemptiv
therapi
patient
monitor
regular
interv
develop
cmv
viremia
patient
viral
replic
treat
antivir
therapi
ganciclovir
prevent
cmv
diseas
univers
cmv
prophylaxi
hand
give
risk
patient
antivir
therapi
defin
durat
prevent
develop
diseas
isol
identif
cmv
blood
clinic
specimen
use
tradit
cell
cultur
technolog
shell
vial
cultur
lack
suffici
sensit
provid
quantit
viral
load
cmv
antigenemia
test
detect
protein
cmv
within
polymorphonuclear
leukocyt
blood
provid
semiquantit
result
specif
marker
activ
earli
infect
newer
molecular
test
increasingli
use
cmv
due
increas
sensit
earlier
detect
viremia
standard
avail
molecular
test
world
health
organ
nation
institut
scienc
technolog
standard
cmv
ebv
associ
case
ptld
highest
rate
ptld
seen
first
year
transplant
howev
case
repres
onefifth
cumul
ptld
burden
ptld
develop
within
first
year
transplant
present
mononucleosislik
syndrom
later
develop
fulmin
malign
diseas
mortal
first
year
lateonset
ptld
present
nonhodgkin
lymphoma
treatment
includ
chemotherapi
reduct
immunosuppress
sinc
ebv
replic
usual
preced
onset
clinic
symptom
grow
interest
use
sensit
molecular
ebv
test
detect
earli
ebvassoci
ptld
method
need
standard
standard
avail
quantit
pcr
assay
use
consist
differ
normal
peripher
blood
viral
load
healthi
carrier
viral
load
detect
ptld
patient
test
ebv
viral
load
may
assist
earli
detect
ii
preemptiv
therapeut
intervent
iii
evalu
therapeut
effect
final
lt
patient
mani
common
respiratori
virus
caus
morbid
mortal
ht
popul
includ
influenza
viru
rsv
parainfluenza
viru
human
metapneumoviru
season
virus
appear
gener
popul
virus
caus
rang
diseas
sever
rhinorrhea
pneumonia
transplant
recipi
higher
risk
complic
virus
sot
recipi
fungi
play
import
role
caus
infect
ht
patient
includ
candida
spp
c
neoforman
p
jirovecii
dimorph
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
filament
mold
includ
aspergillu
spp
candida
spp
common
caus
invas
fungal
infect
among
sot
recipi
candida
infect
vari
sever
mucos
involv
fungemia
dissemin
diseas
less
seriou
mucos
infect
occur
time
transplant
sever
infect
usual
occur
complic
hospit
candidemia
usual
result
indwel
cathet
use
broadspectrum
antimicrobi
agent
candidemia
result
dissemin
diseas
involv
liver
spleen
kidney
heart
eye
invas
candidiasi
gener
occur
within
month
transplant
diagnosi
made
via
scrape
biopsi
mucos
surfac
posit
cultur
steril
site
histolog
stain
involv
organ
diagnosi
commonli
establish
cultur
sinc
candida
spp
easili
grown
routin
media
use
mycolog
laboratori
readili
identifi
commerci
avail
system
treatment
infect
transplant
recipi
similar
treatment
nontranspl
recipi
base
infecti
diseas
societi
america
guidelin
cryptococcosi
third
common
fungal
infect
follow
ht
procedur
overal
incid
ht
recipi
rang
cryptococc
diseas
usual
develop
inhal
organ
syndrom
begin
pulmonari
diseas
follow
dissemin
organ
propens
caus
mening
osteomyel
cellul
one
report
ht
recipi
dissemin
diseas
pulmonari
diseas
skin
soft
tissu
bone
involv
patient
suspect
cryptococcosi
lumbar
punctur
blood
urin
cultur
determin
extent
diseas
diagnosi
usual
made
detect
cryptococc
polysaccharid
capsular
antigen
serum
andor
cerebrospin
fluid
csf
recoveri
organ
cultur
histolog
detect
organ
tissu
use
mucicarmin
capsul
stain
treatment
includ
amphotericin
b
flucytosin
follow
fluconazol
recent
data
suggest
lipid
formul
amphotericin
b
significantli
improv
outcom
ht
recipi
cn
cryptococcosi
p
jirovecii
pneumonia
pjp
occur
ht
recipi
prior
introduct
effect
prophylaxi
usual
occur
first
month
follow
transplant
without
prophylaxi
incid
decreas
due
prophylaxi
well
reduct
corticosteroid
use
organ
transplant
clinic
present
pjp
usual
subacut
dyspnea
nonproduct
cough
hypoxemia
diagnosi
made
methenamin
silver
stain
stain
induc
sputum
bronchioalveolar
lavag
specimen
specif
immunofluoresc
stain
also
use
success
treatment
highdos
tmpsmx
recommend
patient
hypoxemia
adjunct
corticosteroid
administ
well
high
incid
pcp
prophylaxi
tmpsmx
month
ht
recommend
dapson
often
use
secondlin
agent
mycot
infect
caus
dimorph
fungi
also
occur
ht
recipi
result
reactiv
previous
dormant
infect
result
new
exposur
histoplasma
infect
rare
posttransplant
estim
incid
area
endem
infect
occur
inhal
organ
frequent
result
pulmonari
diseas
infect
clear
transplant
recipi
develop
dissemin
diseas
involv
liver
spleen
bone
marrow
mucosa
skin
symptom
includ
fever
chill
malais
fatigu
diagnosi
made
cultur
affect
tissu
histolog
examin
method
diagnosi
includ
h
capsulatum
capsular
polysaccharid
antigen
test
blood
urin
eia
situ
hybrid
treatment
amphotericin
b
follow
itraconazol
recommend
coccidioidomycosi
incid
follow
ht
area
endem
usual
occur
inhal
organ
reactiv
previous
contain
diseas
c
immiti
usual
dissemin
quickli
transplant
recipi
caus
mening
osteomyel
transplant
recipi
develop
fever
headach
nuchal
rigid
alter
mentat
cn
coccidioidomycosi
fatal
patient
diagnosi
made
histolog
visual
uniqu
spherul
c
immiti
c
immiti
may
easili
infect
laboratori
personnel
appropri
safeti
precaut
must
institut
growth
mold
coloni
suggest
possibl
organ
bronchoalveolar
lavag
fluid
csf
tissu
prefer
specimen
diagnosi
sputum
may
also
cultur
howev
case
sputum
product
may
scant
treatment
coccidioidomycosi
amphotericin
b
follow
fluconazol
recommend
blastomycosi
infrequ
describ
opportunist
infect
follow
ht
diseas
result
pneumonia
follow
extrapulmonari
dissemin
often
skin
diagnosi
blastomycosi
made
cultur
histolog
dimorph
mold
safeti
precaut
warrant
suspect
coloni
treatment
amphotericin
b
firstlin
therapi
follow
itraconazol
recommend
incid
invas
aspergillosi
ht
recipi
rang
aspergillu
usual
inhal
environ
caus
pneumon
sinus
organ
quickli
dissemin
caus
signific
morbid
mortal
one
studi
mortal
rate
ht
recipi
invas
aspergillosi
aspergillu
frequent
caus
cn
infect
organ
involv
independ
poor
prognost
factor
among
sot
patient
includ
hepat
insuffici
malnutrit
cn
diseas
make
diagnosi
aspergillu
infect
difficult
definit
method
diagnosi
includ
microbiolog
histolog
confirm
cultur
respiratori
tract
lack
sensit
posit
cultur
necessarili
indic
invas
diseas
ht
recipi
posit
predict
valu
posit
aspergillu
cultur
respiratori
tract
therefor
method
use
aid
diagnosi
includ
galactomannan
test
test
radiograph
find
consist
pulmonari
diseas
halo
sign
cultur
recoveri
mold
normal
steril
site
treatment
invas
aspergillosi
usual
includ
prompt
initi
voriconazol
lipid
formul
amphotericin
b
voriconazol
drug
choic
treatment
invas
aspergillosi
patient
includ
sot
recipi
echinocandin
may
also
play
adjunct
role
mold
infect
report
ht
recipi
includ
zygomycosi
fusariosi
phaeohyphomycosi
cultur
usual
reli
upon
establish
diagnosi
infect
although
home
brew
molecular
test
develop
detect
fungi
method
poorli
standard
two
parasit
infect
worth
note
ht
recipi
caus
problem
popul
sot
recipi
first
trypansoma
cruzi
caus
american
trypanosomiasi
second
toxoplasma
gondii
caus
toxoplasmosi
two
parasit
play
import
role
specif
infect
heart
transmit
via
donor
organ
cruzi
occur
central
south
america
area
endem
chagas
cardiomyopathi
third
lead
caus
ht
infect
heart
transplant
reactiv
transplant
occur
recipi
two
report
acut
chaga
infect
organ
transplant
unscreen
donor
publish
us
transplant
candid
live
region
endem
serolog
test
cruzi
infect
either
donor
recipi
seroposit
parasitemia
occur
recipi
recipi
receiv
benznidazol
month
addit
close
monitor
first
week
monthli
thereaft
make
sure
reactiv
occur
gondii
serolog
test
done
cardiac
donor
recipi
organ
persist
latent
myocardium
common
present
toxoplasmosi
myocard
dissemin
oppos
enceph
diagnosi
infect
perform
histolog
serolog
adequ
diagnosi
reactiv
gondii
infect
treatment
gondii
infect
includ
pyrimethamin
sulfadiazin
folat
rescu
leucovorin
serolog
test
posit
ht
recipi
receiv
prophylaxi
tmpsmx
pyrimethamin
without
prophylaxi
seroposit
patient
develop
symptomat
infect
usual
within
month
transplant
routin
use
tmpsmx
pcp
prophylaxi
decreas
risk
posttranspl
toxoplasmosi
